Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Spotify
SPOT
|
+$189M |
| 2 |
Boeing
BA
|
+$57.2M |
| 3 |
Carvana
CVNA
|
+$23.2M |
| 4 |
ConocoPhillips
COP
|
+$22.6M |
| 5 |
EXE
Expand Energy Corporation Common Stock
EXE
|
+$19.6M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$500M |
| 2 |
Microsoft
MSFT
|
+$426M |
| 3 |
Amazon
AMZN
|
+$245M |
| 4 |
Meta Platforms (Facebook)
META
|
+$194M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$167M |
Sector Composition
| 1 | Technology | 33.9% |
| 2 | Consumer Discretionary | 12.65% |
| 3 | Healthcare | 10.7% |
| 4 | Communication Services | 9.68% |
| 5 | Industrials | 8.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1626
Celldex Therapeutics
CLDX
$1.67B
| $2.96M | ﹤0.01% |
117,300
+1,400
| +1% | +$35.4K |
|
1627
Dynavax Technologies
DVAX
$1.14B
| $2.96M | ﹤0.01% |
231,978
-12,100
| -5% | -$155K |
|
1628
Dana Inc
DAN
$2.73B
| $2.96M | ﹤0.01% |
256,100
| – | – |
|
1629
Adient
ADNT
$1.92B
| $2.95M | ﹤0.01% |
171,498
-3,900
| -2% | -$67.2K |
|
1630
Greif
GEF
$3.54B
| $2.95M | ﹤0.01% |
48,300
+400
| +0.8% | +$24.4K |
|
|
LTC
1631
LTC Properties
LTC
$1.68B
| $2.95M | ﹤0.01% |
85,362
| – | – |
|
1632
Nelnet
NNI
$4.44B
| $2.95M | ﹤0.01% |
27,600
| – | – |
|
1633
Integra LifeSciences
IART
$1.21B
| $2.94M | ﹤0.01% |
129,694
-1,400
| -1% | -$31.8K |
|
1634
AtriCure
ATRC
$1.75B
| $2.93M | ﹤0.01% |
95,800
+700
| +0.7% | +$21.4K |
|
1635
Vermilion Energy
VET
$1.18B
| $2.92M | ﹤0.01% |
310,667
-4,200
| -1% | -$39.5K |
|
1636
National Healthcare
NHC
$1.76B
| $2.92M | ﹤0.01% |
27,130
| – | – |
|
1637
Photronics
PLAB
$1.3B
| $2.92M | ﹤0.01% |
123,800
| – | – |
|
1638
AMC Entertainment Holdings
AMC
$1.44B
| $2.92M | ﹤0.01% |
732,491
+155,500
| +27% | +$619K |
|
1639
Ingevity
NGVT
$2.08B
| $2.91M | ﹤0.01% |
71,490
+4,100
| +6% | +$167K |
|
1640
Hope Bancorp
HOPE
$1.41B
| $2.91M | ﹤0.01% |
236,557
| – | – |
|
1641
BioCryst Pharmaceuticals
BCRX
$1.68B
| $2.91M | ﹤0.01% |
386,568
+22,600
| +6% | +$170K |
|
1642
Mirum Pharmaceuticals
MIRM
$3.82B
| $2.91M | ﹤0.01% |
70,300
+1,300
| +2% | +$53.8K |
|
1643
Veritex Holdings
VBTX
$1.87B
| $2.91M | ﹤0.01% |
107,017
| – | – |
|
1644
Helios Technologies
HLIO
$1.82B
| $2.91M | ﹤0.01% |
65,100
| – | – |
|
1645
Kornit Digital
KRNT
$662M
| $2.9M | ﹤0.01% |
93,800
| – | – |
|
1646
Surgery Partners
SGRY
$2.75B
| $2.9M | ﹤0.01% |
137,100
| – | – |
|
1647
Tarsus Pharmaceuticals
TARS
$2.19B
| $2.9M | ﹤0.01% |
52,333
+600
| +1% | +$33.2K |
|
1648
Arcutis Biotherapeutics
ARQT
$2.11B
| $2.88M | ﹤0.01% |
206,900
+3,300
| +2% | +$46K |
|
1649
Customers Bancorp
CUBI
$2.35B
| $2.88M | ﹤0.01% |
59,200
+600
| +1% | +$29.2K |
|
1650
Vita Coco
COCO
$2.19B
| $2.88M | ﹤0.01% |
78,000
| – | – |
|